All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Millennium Pharmaceuticals Inc. filed a new drug application for Velcade, a proteasome inhibitor shown to extend median survival time in relapsed and refractory multiple myeloma patients to 16.4 months. (BioWorld Today)